Who is sponsoring NCT06604767?

NCT06604767 is sponsored by Sanofi Pasteur, a Sanofi Company.

What drugs are being tested in NCT06604767?

Interventions in NCT06604767: parainfluenza virus type 3 vaccine (PIV3), RSV/hMPV/PIV3 vaccine, RSV/hMPV vaccine, RSV vaccine 1, RSV vaccine 2.

What condition does NCT06604767 study?

NCT06604767 studies Respiratory Syncytial Virus Infection, Metapneumovirus Infection, Parainfluenzae Virus Infection.

Is NCT06604767 still recruiting?

NCT06604767 is currently active, enrolled. Last updated 22 January 2026.

Last reviewed 2026-01-22 · How we verify

NCT06604767

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of a Respiratory Syncytial Virus/Human Metapneumovirus/Parainfluenza Virus Type 3 Vaccine Candidate in Adults Aged 60 Years and Older

Active, enrolled Phase 1 Last updated 22 January 2026

What this trial tests

Phase 1 trial testing parainfluenza virus type 3 vaccine (PIV3) in Respiratory Syncytial Virus Infection in 390 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

17 September 2024

Primary endpoint
25 March 2026

25 March 2026

Quick facts

Lead sponsor	Sanofi Pasteur, a Sanofi Company
Phase	Phase 1
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	prevention
Enrollment	390
Start date	17 September 2024
Primary completion	25 March 2026
Estimated completion	25 March 2026
Sites	8 locations across Australia

Drugs / interventions tested

parainfluenza virus type 3 vaccine (PIV3) — full drug profile →
RSV/hMPV/PIV3 vaccine — full drug profile →
RSV/hMPV vaccine
RSV vaccine 1
RSV vaccine 2

Conditions studied

Respiratory Syncytial Virus Infection — all drugs for Respiratory Syncytial Virus Infection →
Metapneumovirus Infection — all drugs for Metapneumovirus Infection →
Parainfluenzae Virus Infection — all drugs for Parainfluenzae Virus Infection →

Sponsor

Sanofi Pasteur, a Sanofi Company — full company profile →

Who can join

60 and older, any sex, with Respiratory Syncytial Virus Infection or Metapneumovirus Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this phase 1 study is to evaluate whether the vaccine is safe and can help the body to develop germ fighting agents called "antibodies" (immunogenicity) against the respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and parainfluenza virus type 3 (PIV3). The study will use different doses of PIV3 only and different combinations of RSV/hMPV/PIV3 or RSV/hMPV or only RSV vaccine in adults aged 60 years and older.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Vaccine Development for Human Pneumoviruses.
Mboup EB, Hamelin MÈ, Dubois J, Rosa-Calatrava M, et al · · 2025 · cited 8× · PMID 40573900 · DOI 10.3390/vaccines13060569
Landscape of Prophylactic Strategies Against Human Parainfluenza Virus Type 3.
Vacher C, Dubois J, Hamelin ME, Boivin G, et al · · 2025 · cited 2× · PMID 41066648 · DOI 10.1002/rmv.70071
Respiratory syncytial virus (RSV) antibody and small-molecule drugs: current status of clinical translation and challenges.
Liu H, Zhong H, Liu H. · · 2026 · PMID 41743135 · DOI 10.3389/fmicb.2026.1745808

Verify or expand the search:

Other recruiting trials for Respiratory Syncytial Virus Infection

Currently open trials in the same condition.

NCT07402512 — A Phase III Study of Deuremidevir Hydrobromide for the Treatment of RSV Infection in Infants and Young Children · Phase 3 · recruiting
NCT06817889 — Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised Individuals · Phase 2 · recruiting
NCT07239583 — Genotype and Disease Burden of RSV in Older Vietnamese Adults (RSV: Respiratory Syncytial Virus ) · recruiting
NCT06546800 — SPECIAL INVESTIGATION FOR ABRYSVO IN INDIVIDUALS AGED 60 YEARS OR OLDER · active not recruiting

Other Sanofi Pasteur, a Sanofi Company trials

Trials by the same sponsor.

NCT07536048 — A Longitudinal Study of Epstein-Barr Virus (EBV) Reactivation in Adults Aged 18 to 29 Years · not yet recruiting
NCT07222059 — Phase 3 Single Arm, Open Study on vYF in Adults · Phase 3 · completed
NCT07013747 — Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Participants With Mild Acne · Phase 1, PHASE2 · recruiting
NCT06838000 — Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) i · Phase 3 · active not recruiting
NCT06793826 — Post-marketing Surveillance Study for the Safety of a DTaP-IPV- HB-PRP~T Vaccine in Republic of Korea · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06604767 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sanofi Pasteur, a Sanofi Company
Last refreshed: 22 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06604767.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing